Abstract The Japanese Society of Gastroenterology revised the evidence-based clinical
practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected …

Primary sclerosing cholangitis (PSC) is a rare, but serious, cholestatic disease for which, to
date, no effective therapy exists to halt disease progression toward end‐stage liver disease …

Spontaneous bacterial peritonitis (SBP) is a common, life‐threatening complication of liver
cirrhosis. Third‐generation cephalosporins have been considered the first‐line treatment of …

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, which in the
majority of patients progresses to liver transplantation or death. To date, no medical …

Sclerosing cholangitis is a chronic disorder characterized by inflammation and progressive
obliterative fibrosis of the intrahepatic and/or extrahepatic bile ducts. It has long been …

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that progresses to
end-stage liver disease and cirrhosis. Recurrent biliary inflammation is thought to lead to …

All possible direct-acting antiviral agent (DAA) regimens for treatment-naive hepatitis C
genotype 1 were evaluated by many randomized controlled trials (RCTs). However, the …

Ursodeoxycholic acid (UDCA) was reported to reduce bile acid toxicity, but the mechanisms
underlying its cytoprotective effects are not fully understood. The aim of the present study …

胆汁淤积(cholestasis) 的定义为由于遗传缺陷, 机械性障碍, 免疫系统调节异常,
毒素作用等因素损伤胆管, 导致胆汁形成和分布障碍, 造成肠道胆汁缺乏, 而过多潜在毒性的胆汁 …

Primary sclerosing cholangitis (PSC) is a rare, but serious, cholestatic disease for which, to
date, no effective therapy exists to halt disease progression toward end‐stage liver disease …